Details of the Drug Reposition

General Information of This Drug (ID: DMZI4OV)

Drug Name
QLT-091001   DMZI4OV
Synonyms
Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Restless legs syndrome DISNWY00 7A80 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Retinitis pigmentosa DISCGPY8 9B70 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 QLT Begins Dosing In Phase 2 Trial Of QLT091001 For Impaired Dark Adaptation. RTT NEWS. 12/9/2013.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)